Investors welcomed fiscal austerity measures in Greece but remained wary of a sustained recovery. The markets traded near the flat line with the Dow rising 5 points to 10,439. Nasdaq slipped 2 points to 2304.
On the upside
An 18 month filing delay for Roche's diabetes treatment taspoglutide lifted shares of Alkermes (Nasdaq: ALKS), Amylin Pharmaceuticals (Nasdaq: AMLN) and Eli Lilly (NYSE: LLY), which are awaiting regulatory approval of their once a week diabetes drug Bydureon.
Actuant (NYSE: ATU) reversed year ago losses to post a third quarter profit as revenue rose.
Boston Scientific (NYSE: BSX) reported cardiac resynchronization therapy improved conditions in both men and women but women received much greater benefit from the therapy.
On the downside
Wimm-Bill-Dann (NYSE: WBD) expressed interest in purchasing Danone's 18% stake in the company.
Adolor (Nasdaq: ADLR) reported that two pain medications, ADL5859 and ADL5747, failed a midstage clinical trail.
Banner (NYSE: BANR) will offer $150 million worth of common shares through a public offering.
In the broad market, advancing issues outpaced decliners by a margin of nearly 10 to 9 on the NYSE while decliners edged out advancers by nearly 9 to 7 on Nasdaq. The Russell 2000 which tracks small cap stocks eased a fraction to 665.
